SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S.

Apricus Biosciences, Inc.’s APRI shares gained 7.7% after the company announced that it has entered into a license agreement with Allergan AGN under which it will regain the U.S. development and ...

NEW YORK (AP) -- Apricus Biosciences Inc. said Monday that its impotence drug Vitaros has been approved in 10 European countries. The company said Vitaros is now approved in the Netherlands, Germany, ...

(Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the ...

SAN FRANCISCO, Jan. 12, 2011 (GLOBE NEWSWIRE) -- Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), today presented at the Fourth ...

What it does: Develops new formulations of government-approved drugs using its patented NexACT molecules, which loosen so-called tight junctions that bind skin cells to each other, creating space for ...

SAN DIEGO, April 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences ("Apricus Bio") (Nasdaq:APRI) () is building a strong product pipeline backed by a sound financial position, Chairman, President and ...

Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not ...

Apricus Biosciences has continued to launch their novel treatment of Erectile Dysfunction throughout Europe. The company has fallen 20% since the first launch even though the short rate has also ...